PB 14 of 2025

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 2)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated  24 February 2025

REBECCA RICHARDSON

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015). 2

1 Name

1.            This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 2).
2.            This instrument may also be cited as PB 14 of 2025.

2 Commencement

1.            Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1.            Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

1.            Schedule 1, after entry for Donepezil in the form Tablet containing donepezil hydrochloride 10 mg

insert:

1.            Schedule 1, after entry for Estradiol in the form Tablet containing estradiol valerate 2 mg

insert:

1.            Schedule 1, after entry for Estradiol in the form Transdermal patches 1.56 mg, 8

insert:

1.            Schedule 1, after entry for Estradiol with norethisterone in the form Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

insert:

1.            Schedule 1, after entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

insert:

1.            Schedule 1, after entry for Probenecid

insert:

1.            Schedule 2, after entry for Acarbose in the form Tablet 50 mg

insert:

1.            Schedule 2, after entry for Acarbose in the form Tablet 100 mg

insert:

1.            Schedule 2, after entry for Doxycycline in the form Tablet 50 mg (as monohydrate)

insert:

1.        Schedule 2, after entry for Estradiol in the form Tablet containing estradiol valerate 2 mg

insert:

1.        Schedule 2, after entry for Estradiol with norethisterone in the form Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8

insert:

1.        Schedule 2, after entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

insert:

1.        Schedule 2, after entry for Fluoxetine

insert:

1.        Schedule 2, entry for Gliclazide

insert as first entry:

1.        Schedule 2, after entry for Probenecid

insert: